We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-15.48%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$504M
AUM Growth
-$158M
Cap. Flow
-$56.6M
Cap. Flow %
-11.24%
Top 10 Hldgs %
27.49%
Holding
102
New
6
Increased
45
Reduced
33
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$10M
2
ALKS icon
Alkermes
ALKS
+$9.75M
3
ENDP
Endo International plc
ENDP
+$6.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.86M
5
GILD icon
Gilead Sciences
GILD
+$5.05M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$11.5M
2
MDT icon
Medtronic
MDT
+$8.44M
3
HNT
HEALTH NET INC
HNT
+$8.35M
4
ABMD
Abiomed Inc
ABMD
+$8.02M
5
CVS icon
CVS Health
CVS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 93.13%
2 Financials 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
26
Cardinal Health
CAH
$55.4B
$7.54M 1.5%
92,000
-12,000
-12% -$976K
AET
27
DELISTED
Aetna Inc
AET
$7.53M 1.49%
67,000
-37,000
-36% -$3.96M
ABBV icon
28
AbbVie
ABBV
$435B
$7.43M 1.47%
130,000
-116,000
-47% -$6.47M
ENDP
29
DELISTED
Endo International plc
ENDP
$7.32M 1.45%
260,000
+144,000
+124% +$6.8M
ESRX
30
DELISTED
Express Scripts Holding Company
ESRX
$7.28M 1.45%
106,000
+32,000
+43% +$2.3M
NKTR icon
31
Nektar Therapeutics
NKTR
$2.58B
$7.22M 1.43%
35,000
-3,733
-10% -$717K
AMGN icon
32
Amgen
AMGN
$222B
$6.75M 1.34%
45,000
-37,000
-45% -$5.5M
ELV icon
33
Elevance Health
ELV
$85.5B
$6.53M 1.3%
47,000
-41,000
-47% -$5.48M
MCK icon
34
McKesson
MCK
$101B
$6.29M 1.25%
40,000
-19,000
-32% -$3.07M
VRTX icon
35
Vertex Pharmaceuticals
VRTX
$126B
$6.2M 1.23%
78,000
+22,000
+39% +$1.99M
COO icon
36
Cooper Companies
COO
$14.5B
$6.16M 1.22%
160,000
+12,000
+8% +$414K
COR icon
37
Cencora
COR
$61.2B
$5.45M 1.08%
63,000
+17,000
+37% +$1.51M
DXCM icon
38
DexCom
DXCM
$32B
$5.09M 1.01%
300,000
-120,000
-29% -$2M
CPHD
39
DELISTED
Cepheid Inc
CPHD
$5M 0.99%
150,000
+75,000
+100% +$2.35M
HUM icon
40
Humana
HUM
$46.2B
$4.94M 0.98%
27,000
-34,000
-56% -$5.9M
EW icon
41
Edwards Lifesciences
EW
$51.7B
$4.85M 0.96%
165,000
+18,000
+12% +$497K
CERN
42
DELISTED
Cerner Corp
CERN
$4.55M 0.9%
86,000
+4,000
+5% +$218K
KERX
43
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$4.44M 0.88%
950,000
-283,000
-23% -$1.13M
ZLTQ
44
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$4.35M 0.86%
160,000
+32,000
+25% +$754K
REGN icon
45
Regeneron Pharmaceuticals
REGN
$80.8B
$4.33M 0.86%
12,000
-9,000
-43% -$3.71M
CYH icon
46
Community Health Systems
CYH
$423M
$4.17M 0.83%
272,250
+157,300
+137% +$2.4M
SUPN icon
47
Supernus Pharmaceuticals
SUPN
$2.77B
$4.12M 0.82%
270,000
-18,000
-6% -$235K
HALO icon
48
Halozyme
HALO
$12.2B
$4.08M 0.81%
431,000
+21,000
+5% +$198K
JAZZ icon
49
Jazz Pharmaceuticals
JAZZ
$16.7B
$3.92M 0.78%
30,000
-12,000
-29% -$1.49M
ARIA
50
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.83M 0.76%
600,000
+170,000
+40% +$953K
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rhenman & Partners Asset Management held 102 positions worth $504M, down 24% from $661M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $56.6M in Q1 2016, closing 10 positions and reducing 33 holdings. Its most notable exit was HEALTH NET INC, an estimated $8.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Biogen worth $9.89M.

  • Rhenman & Partners Asset Management's largest Q1 2016 buy was Biogen: 38,000 shares worth $9.89M.
  • Rhenman & Partners Asset Management added most to Alkermes in Q1 2016, an estimated $9.75M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2016 reduction was Perrigo, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited HEALTH NET INC in Q1 2016, selling an estimated $8.35M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $504M portfolio in Q1 2016.
  • Rhenman & Partners Asset Management opened 6 new positions and closed 10 in Q1 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $504M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2016, filed 19 Apr 2016.